What the FDA labels say about taking them together
Elagolix and rifampin
Elagolix's FDA label of December 19, 2025 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name elagolix. The elagolix label: “Concomitant use of ORILISSA 200 mg twice daily and rifampin is not recommended.”
Check it at the source: the elagolix FDA label on DailyMed (effective December 19, 2025, AbbVie Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the elagolix label say about rifampin?
Elagolix label, drug interactionsConcomitant use of ORILISSA 200 mg twice daily and rifampin is not recommended.
Source: FDA drug label (Orilissa), AbbVie Inc., effective December 19, 2025 (SPL set a86757b3-09c5-fd3b-1223-244e94f50a66), via openFDA; the full label on DailyMed
What does the rifampin label say about elagolix?
Rifampin's label (effective February 11, 2026) does not name elagolix in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Elagolix | Rifampin | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $43.81 per tablet 150 mg tablet | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once